Current update on synopsis of miRNA dysregulation in neurological disorders

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 4, 2015, Pages 492-501

  Kamal, Mohammad A ^a   Mushtaq, Gohar ^a   Greig, Nigel H ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer disease; Amyotrophic lateral sclerosis; Autism; Huntington disease; MicroRNA; Neurodegeneration; Parkinson s disease; Postmortem brain tissue; Schizophrenia

Indexed keywords

MICRORNA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTISM; DRUG DESIGN PROGRAM; HUMAN; HUNTINGTON CHOREA; IMMUNE DYSREGULATION; INFLAMMATION; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; SCHIZOPHRENIA; ANIMAL; BRAIN; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; HUMANS; MICRORNAS; NERVOUS SYSTEM DISEASES; OXIDATIVE STRESS;

EID: 84929618494     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150225143637     Document Type: Article

References (106)

1. Johnson R, Noble W, Tartaglia GG, Buckley NJ. Neurodegeneration as an RNA disorder. Prog Neurobiol 2012; 99: 293-315.
2. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007; 8(2): 93-103.
3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75(5): 843-54.
4. Cuellar TL, McManus MT. MicroRNAs and endocrine biology. J Endocrinol 2005; 187(3): 327-32.
5. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433(7027): 769-73.
6. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303(5654): 83-6.
7. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432(7014): 226-30.
8. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 2003; 9: 1274-81.
9. Mirnezami AH, Pickard K, Zhang L, Primrose JN, Packham G. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol 2009; 35: 339-47.
10. Aliev G, Obrenovich ME, Reddy VP, et al. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev Med Chem 2008; 8(13): 1395-406.
11. Kosenko EA, Solomadin IN, Tikhonova LA, Reddy VP, Aliev G, Kaminsky YG. Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-β peptides, systemic ammonia and erythrocyte energy metabolism. CNS Neurol Disord Drug Targets 2014; 13(1): 112-9.
12. Aliev G, Priyadarshini M, Reddy VP, et al. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr Med Chem 2014; 21(19): 2208-17.
13. Aliyev A, Seyidova D, Rzayev N, et al. Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease? Neurol Res 2004; 26(5): 547-53.
14. Nunomura A, Perry G, Pappolla MA, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999; 19: 1959-64.
15. Nunomura A, Moreira PI, Castellani RJ, et al. Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox Res 2012; 22(3): 231-48.
16. Moreira PI, Nunomura A, Nakamura M, et al. Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med 2008; 44(8): 1493-505.
17. Honda K, Smith MA, Zhu X, et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox active iron. J Biol Chem 2005; 280: 20978-86.
18. Fatemi N, Sanati MH, Shamsara M, et al. TBHP-induced oxidative stress alters microRNAs expression in mouse testis. J Assist Reprod Genet 2014; 31(10): 1287-93.
19. Zhang R, Zhang Q, Niu J, et al. Screening of microRNAs associated with Alzheimer's disease using oxidative stress cell model and different strains of senescence accelerated mice. J Neurol Sci 2014; 338(1-2): 57-64.
20. Xu S, Zhang R, Niu J, et al. Oxidative stress mediated-alterations of the microRNA expression profile in mouse hippocampal neurons. Int J Mol Sci 2012; 13(12): 16945-60.
21. Alzheimer's Association 2010 Alzheimer's Disease: Facts and figures. Alzheimer's Association, Chicago, IL, 2010.
22. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007; 20: 380-5.
23. Mushtaq G, Khan JA, Kamal MA. Biological Mechanisms linking Alzheimer's disease and Type 2 Diabetes Mellitus. CNS Neurol Disord Drug Targets 2014; 13(7): 1192-201.
24. Klein WL. Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimer's Dement 2006; 2(1): 43-55.
25. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298(5594): 789-91.
26. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44(1): 181-93.
27. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. beta- Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380(6570): 168-71.
28. Orsucci D, Mancuso M, Ienco EC, Simoncini C, Siciliano G, Bonuccelli U. Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease. Curr Neurovasc Res 2013; 10(1): 76-80.
29. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101: 1172-84.
30. Hebert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 2009; 32: 199- 206.
31. Schonrock N, Gotz J. Decoding the non-coding RNAs in Alzheimer's disease. Cell Mol Life Sci 2012; 69: 3543-59.
32. Hebert SS, Horre K, Nicolai L, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 2008; 105: 6415-20.
33. Hebert SS, Horre K, Nicolai L, et al. MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis 2009; 33: 422-8.
34. Schonrock N, Ke YD, Humphreys D, et al. Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid-β. PLoS ONE 2010; 5(6): e11070.
35. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007; 18(3): 297-300.
36. Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 2008; 14: 27-41.
37. Schipper HM, Maes OC, Chertkow HM, Wang E. MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Biol 2007; 1: 263-74.
38. Stoicea N, Wilson T, Chandrasekhar K, Bergese SD. The Role of microRNAs as Potential Biomarkers in Central Nervous System Disorders. Int J Clin Anesthesiol 2013; 1: 1009.
39. Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008; 28: 1213-23.
40. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis 2008; 13: 241-53.
41. Mushtaq G, Khan JA, Kumosani TA, Kamal MA. Alzheimer's disease and Type 2 Diabetes via Chronic Inflammatory Mechanisms. Saudi J Biol Sci 2015; 22(1): 4-13.
42. Lukiw WJ, Zhao Y, Cui JG. An NF-kappa-B sensitive microRNA- 146a mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008; 283: 31315-22.
43. Sethi P, Lukiw WJ. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci Lett 2009; 459: 100-4.
44. Wang LL, Huang Y, Wang G, Chen SD. The potential role of microRNA-146 in Alzheimer's disease: biomarker or therapeutic target? Med Hypotheses 2012; 78: 398-401.
45. Li YY, Cui JG, Dua P, Pogue AI, Bhattacharjee S, Lukiw WJ. Differential expression of miRNA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells. Neurosci Lett 2011; 499: 109-113.
46. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology 2007; 68: 326-37.
47. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007; 16(S2): R183-94.
48. Goetz CG. The history of Parkinson's disease: Early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 2011; 1(1): a008862.
49. Shtilbans A, Henchcliffe C. Biomarkers in Parkinson's disease: an update. Curr Opin Neurol 2012; 25: 460-5.
50. Mouradian MM. MicroRNAs in Parkinson's disease. Neurobiol Dis 2012; 46: 279-84.
51. Maciotta S, Meregalli M, Torrente Y. The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 2013; 7: 265.
52. Kim J, Inoue K, Ishii J, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007; 317: 1220-4.
53. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388 (6645): 839-40.
54. Sotiriou S, Gibney G, Baxevanis AD, Nussbaum RL. A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci Lett 2009; 461: 196-201.
55. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by miR-7 and miR-153. J Biol Chem 2010; 285: 12726- 34.
56. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Repression of alpha- synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 2009; 106: 13052-7.
57. Alvarez-Erviti L, Seow Y, Schapira AH, Rodriguez-Oroz MC, Obeso JA, Cooper JM. Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease. Cell Death Dis 2013; 4: e545.
58. Winslow AR, Rubinsztein DC. The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy 2011; 7: 429-31.
59. Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinson's disease. J Biotechnol 2011; 152: 96-101.
60. Cardo LF, Coto E, DeMena L, et al. Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J Neurol 2013; 260: 1420-2.
61. Mates JM, Perez-Gomez C, Nunez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem 1999; 32: 595-603.
62. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-81.
63. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919-30.
64. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008; 412: 191-209.
65. Savas JN, Makusky A, Ottosen S, et al. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc Natl Acad Sci USA 2008; 105: 10820-5.
66. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Bjorkqvist M. Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Hum Mol Genet 2011; 20: 2225-37.
67. Jin J, Cheng Y, Zhang Y, et al. Interrogation of brain miRNA and mRNA expression profiles reveals a molecular regulatory network that is perturbed by mutant huntingtin. J Neurochem 2012; 123: 477-90.
68. Sinha M, Ghose J, Das E, Bhattarcharyya NP. Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP. Biochem Biophys Res Commun 2010; 396: 742-7.
69. Sinha M, Ghose J, Bhattarcharyya NP. MicroRNA-214, -150, - 146a and -125b target Huntingtin gene. RNA Biol 2011; 8: 1005- 21.
70. Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007; 6(11): 994- 1003.
71. Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 2003; 74(7): 995-7.
72. De Felice B, Guida M, Guida M, Coppola C, DeMieri G, Cotrufo R. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 2012; 508: 35-40.
73. Shioya M, Obayashi S, Tabunoki H, et al. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol 2010; 36: 320-30.
74. Campos-Melo D, Droppelmann CA, He Z, Volkening K, Strong MJ. Altered microRNA expression profile in amyotrophic lateral sclerosis: a role in the regulation of NFL mRNA levels. Mol Brain 2013; 6: 26.
75. McCarthy JJ. MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 2008; 1779: 682-91.
76. Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 2012; 124: 339-52.
77. Williams AH, Valdez G, Moresi V, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009; 326: 1549-54.
78. Russell AP, Wada S, Vergani L, et al. Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol Dis 2012; 49C: 107-17.
79. van Os J, Kapur S. Schizophrenia. Lancet 2009; 374(9690): 635- 45.
80. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009; 35(2): 383- 402.
81. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24(4 Suppl): 81- 90.
82. Smith T, Weston C, Lieberman J. Schizophrenia (maintenance treatment). Am Fam Physician 2010; 82(4): 338-9.
83. Perkins DO, Jeffries CD, Jarskog LF, et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007; 8: R27.
84. Beveridge NJ, Tooney PA, Carroll AP, et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 2008; 17: 1156-68.
85. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2010; 15: 1176-89.
86. Karayiorgou M, Morris MA, Morrow B, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci USA 1995; 92: 7612-6.
87. Stark KL, Xu B, Bagchi A, et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet 2008; 40: 751-60.
88. Li F, Tsien JZ. Memory and the NMDA receptors. N Engl J Med 2009; 361(3): 302-3.
89. Miller BH, Zeier Z, Xi L, et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA 2012; 109(8): 3125- 30.
90. Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health 2007; 28: 235- 58.
91. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 2008; 9(5): 341-55.
92. Arndt TL, Stodgell CJ, Rodier PM. The teratology of autism. Int J Dev Neurosci 2005; 23(2-3): 189-99.
93. Rutter M. Incidence of autism spectrum disorders: changes over time and their meaning. Acta Paediatr 2005; 94(1): 2-15.
94. Mushtaq G, Khan JA, Joseph ED, Kamal MA. Nanoparticles, Neurotoxicity and Neurodegenerative Diseases. Curr Drug Metab 2014; (in press).
95. Kern JK, Geier DA, Sykes LK, Geier MR. Evidence of neurodegeneration in autism spectrum disorder. Transl Neurodegener 2013; 2(1): 17.
96. Levy SE, Mandell DS, Schultz RT. Autism. Lancet 2009; 374(9701): 1627-38.
97. Talebizadeh Z, Butler MG, Theodoro MF. Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res 2008; 1: 240-50.
98. Ghahramani Seno MM, Hu P, Gwadry FG, et al. Gene and miRNA expression profiles in autism spectrum disorders. Brain Res 2011; 1380: 85-97.
99. Sarachana T, Zhou R, Chen G, Manji HK, Hu VW. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med 2010; 2: 23.
100. Duffield GE, Watson NP, Mantani A, et al. A role for Id2 in regulating photic entrainment of the mammalian circadian system. Curr Biol 2009; 19: 297-304.
101. Seeburg DP, Feliu-Mojer M, Gaiottino J, Pak DT, Sheng M. Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron 2008; 58: 571- 83.
102. Seeburg DP, Pak D, Sheng M. Polo-like kinases in the nervous system. Oncogene 2005; 24: 292-8.
103. Abu-Elneel K, Liu T, Gazzaniga FS, et al. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 2008; 9: 153-61.
104. Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol 2007; 17(4): 434-47.
105. Gascon E, Gao FB. Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration. Front Neurosci 2012; 6: 48.
106. Miller BH, Wahlestedt C. MicroRNA dysregulation in psychiatric disease Brain Res 2010; 1338: 89-99.